Cargando…
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965052/ https://www.ncbi.nlm.nih.gov/pubmed/35372000 http://dx.doi.org/10.3389/fonc.2022.859152 |
_version_ | 1784678348528549888 |
---|---|
author | Kapeleris, Joanna Ebrahimi Warkiani, Majid Kulasinghe, Arutha Vela, Ian Kenny, Liz Ladwa, Rahul O’Byrne, Kenneth Punyadeera, Chamindie |
author_facet | Kapeleris, Joanna Ebrahimi Warkiani, Majid Kulasinghe, Arutha Vela, Ian Kenny, Liz Ladwa, Rahul O’Byrne, Kenneth Punyadeera, Chamindie |
author_sort | Kapeleris, Joanna |
collection | PubMed |
description | Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC. |
format | Online Article Text |
id | pubmed-8965052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89650522022-03-31 Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update Kapeleris, Joanna Ebrahimi Warkiani, Majid Kulasinghe, Arutha Vela, Ian Kenny, Liz Ladwa, Rahul O’Byrne, Kenneth Punyadeera, Chamindie Front Oncol Oncology Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC. Frontiers Media S.A. 2022-03-15 /pmc/articles/PMC8965052/ /pubmed/35372000 http://dx.doi.org/10.3389/fonc.2022.859152 Text en Copyright © 2022 Kapeleris, Ebrahimi Warkiani, Kulasinghe, Vela, Kenny, Ladwa, O’Byrne and Punyadeera https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kapeleris, Joanna Ebrahimi Warkiani, Majid Kulasinghe, Arutha Vela, Ian Kenny, Liz Ladwa, Rahul O’Byrne, Kenneth Punyadeera, Chamindie Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title_full | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title_fullStr | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title_full_unstemmed | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title_short | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
title_sort | clinical applications of circulating tumour cells and circulating tumour dna in non-small cell lung cancer—an update |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965052/ https://www.ncbi.nlm.nih.gov/pubmed/35372000 http://dx.doi.org/10.3389/fonc.2022.859152 |
work_keys_str_mv | AT kapelerisjoanna clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT ebrahimiwarkianimajid clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT kulasinghearutha clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT velaian clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT kennyliz clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT ladwarahul clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT obyrnekenneth clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT punyadeerachamindie clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate |